[Soluble CD40 ligand: a potential marker of cardiovascular risk].

El ligando CD40 soluble: marcador potencial de riesgo cardiovascular.

Publisher: Elsevier España Country of Publication: Spain NLM ID: 8608576 Publication Model: Print Cited Medium: Print ISSN: 0014-2565 (Print) Linking ISSN: 00142565 NLM ISO Abbreviation: Rev Clin Esp Subsets: MEDLINE

Publication: 2010- : Madrid : Elsevier España
Original Publication: Barcelona : Doyma

CD40 Ligand*/blood ; CD40 Ligand*/genetics; Cardiovascular Diseases/*epidemiology; Abciximab ; Acute Coronary Syndrome/blood ; Acute Coronary Syndrome/drug therapy ; Acute Coronary Syndrome/epidemiology ; Acute Coronary Syndrome/mortality ; Alanine/therapeutic use ; Angina, Unstable/blood ; Angina, Unstable/epidemiology ; Animals ; Antibodies, Monoclonal/therapeutic use ; Anticoagulants/therapeutic use ; Aspirin/therapeutic use ; Atherosclerosis/blood ; Atherosclerosis/epidemiology ; Biomarkers ; Cardiovascular Diseases/blood ; Chromosomes, Human, X/genetics ; Clinical Trials as Topic ; Disease Models, Animal ; Female ; Fibrinolytic Agents/therapeutic use ; Humans ; Immunoglobulin Fab Fragments/therapeutic use ; Mice ; Platelet Activation ; Platelet Aggregation Inhibitors/therapeutic use ; Prognosis ; Pyrrolidines/therapeutic use ; Risk Factors ; Thrombosis/blood ; Thrombosis/epidemiology

Recombinant human soluble CD40 ligand, also named CD145 or gp 39, is a 16.3 kD glycoprotein containing 149 aa residues comprising the receptor binding TNF-like domain of CD40 ligand. It is expressed on antigen-presenting cells such as B cells, macrophages, dendritic cells and thymic epithelial cells and it constitutes the nexus between the inflammatory system and the vascular thrombotic processes. Its gene is located in the long arm of the human X chromosome. Prognostic evaluation of the residual fixed atherosclerotic plaque is insufficient to predict clinical course. Currently, studies have been done that demonstrate the participation of the immunoinflammatory system in the genesis and complications of the atherosclerotic condition. In the future, the most specific biomarkers of vulnerability will be very useful in the daily practice (interleukins, CD40, etc.). The soluble CD40 ligand together with its CD40 receptor are overexpressed in experimental and human atherosclerotic lesions. This leads to an increase of mediators for the development of atherosclerosis. Both significantly contribute to the inflammatory processes that leads to atherosclerosis and thrombosis.

0 (Antibodies, Monoclonal)
0 (Anticoagulants)
0 (Biomarkers)
0 (Fibrinolytic Agents)
0 (Immunoglobulin Fab Fragments)
0 (Platelet Aggregation Inhibitors)
0 (Pyrrolidines)
147205-72-9 (CD40 Ligand)
FGJ53JS7PT (orbofiban)
OF5P57N2ZX (Alanine)
R16CO5Y76E (Aspirin)
X85G7936GV (Abciximab)

Date Created: 20070811 Date Completed: 20071219 Latest Revision: 20190917

20221213

10.1157/13108766

17688874